A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge.
Virol J
; 19(1): 112, 2022 06 27.
Article
in English
| MEDLINE | ID: covidwho-1905664
ABSTRACT
BACKGROUND:
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans, with a case fatality rate of approximately 35%, thus posing a considerable threat to public health. The lack of approved vaccines or antivirals currently constitutes a barrier in controlling disease outbreaks and spread.METHODS:
In this study, using a mammalian expression system, which is advantageous for maintaining correct protein glycosylation patterns, we constructed chimeric MERS-CoV virus-like particles (VLPs) and determined their immunogenicity and protective efficacy in mice.RESULTS:
Western blot and cryo-electron microscopy analyses demonstrated that MERS-CoV VLPs were efficiently produced in cells co-transfected with MERS-CoV spike (S), envelope, membrane and murine hepatitis virus nucleocapsid genes. We examined their ability as a vaccine in a human dipeptidyl peptidase 4 knock-in C57BL/6 congenic mouse model. Mice immunized with MERS VLPs produced S-specific antibodies with virus neutralization activity. Furthermore, MERS-CoV VLP immunization provided complete protection against a lethal challenge with mouse-adapted MERS-CoV and improved virus clearance in the lung.CONCLUSIONS:
Overall, these data demonstrate that MERS-CoV VLPs have excellent immunogenicity and represent a promising vaccine candidate.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Viral Vaccines
/
Coronavirus Infections
/
Vaccines, Virus-Like Particle
/
Middle East Respiratory Syndrome Coronavirus
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Virol J
Journal subject:
Virology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS